From BigGo Finance · BigGo Finance · · 1m 10s
Eddingpharm's GB268 Trial Approved in China
China's NMPA clears Eddingpharm's GB268 Phase 2 colorectal cancer trial.
In brief
China's NMPA clears Eddingpharm's GB268 Phase 2 colorectal cancer trial. Eddingpharm's GB268 Phase 2 trial for advanced colorectal cancer received China's NMPA approval on October 9, targeting the pMMR/MSS subtype that makes up 95% of patients. Originally reported by BigGo Finance.
NMPA Approval
Eddingpharm's GB268 Phase 2 clinical trial for advanced colorectal cancer received China's National Medical Products Administration approval on October 9.
Targeted Patient Population
The pMMR/MSS subtype accounts for approximately 95% of advanced colorectal cancer patients and is insensitive to immune monotherapy.
Clinical Need
Traditional chemotherapy and targeted therapies have reached a plateau in efficacy improvement for this patient group.
GB268 Mechanism
GB268's fine-tuned modulation of pd-1, ctla-4, and vegf activity improves tumor immune microenvironment and inhibits angiogenesis.
Phase 1 Data
Preliminary Phase 1 monotherapy data for gb268 is expected to be presented at ESMO in October 2026.
Breast Cancer Trial
First-patient dosing in a Phase 1b/2 breast cancer trial was completed on August 5, 2026.
Next Steps
Eddingpharm expects gb268 to advance into phase 2 trials across multiple solid tumor types including breast cancer and colorectal cancer.
In short
Eddingpharm's GB268 Phase 2 trial for advanced colorectal cancer received China's NMPA approval on October 9, targeting the pMMR/MSS subtype that makes up 95% of patients.
